United States Patent (10) Patent No.: US 8,399.440 B2 Fogler Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO839944OB2 (12) United States Patent (10) Patent No.: US 8,399.440 B2 Fogler et al. (45) Date of Patent: Mar. 19, 2013 (54) DISEASE MODIFYING ANTI-ARTHRITIC 4,172,132 A 10/1979 Draper et al. ACTIVITY OF 2-METHOXYESTRADIOL 4.212,864 A 7/1980 Tax 4,307,086 A 12, 1981 Tax (75) Inventors: WilliamO O E. Fogler, Rockville, MD (US); 4,522,7584,444,767 A 4,6, 19851984 WETorelli et al. Stacy M.Plum, Arlington, VA (US); 4.552,758. A 1 1/1985 Murphy et al. Carolyn F. Sidor, Chapel Hill, NC (US) (Continued) (73) Assignee: EntreMed, Inc., Rockville, MD (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this RE E. 1943: patent is extended or adjusted under 35 U.S.C. 154(b) by 905 days. (Continued) (21) Appl. No.: 11/726,361 OTHER PUBLICATIONS (22) Filed: Mare 20,a? V.9 2007 Tishler et al., Ann Rheumat Dis, 1992:51(12): 1330-1331.* (Continued) (65) Prior Publication Data US 2007/0231.410A1 Oct. 4, 2007 Primary Examiner — San-Ming Hui (74) Attorney, Agent, or Firm — Suzannah K. Sundby, Esq.; Related U.S. Application Data Smith, Gambrell & Russell, LLP (60) Eyal application No. 60/784,206, filed on Mar. (57) ABSTRACT s The present invention relates a composition for treating rheu (51) Int. Cl. matic diseases. The compositionp comprisesp a compoundp hav A6 IK3I/56 (2006.01) ing the formula A 6LX3L/2197 (2006.01) (52) U.S. Cl. ...................... 514/171; 514/182: 514/252.1 OH (58) Field of Classification Search .................. 514/182, 514/252.02,252.029, 252.1, 171 See application file for complete search history. Ra (56) References Cited U.S. PATENT DOCUMENTS HO 2,584.271 A 2f1952 Huffman 2,846,453 A 8, 1958 Hoehn 3,117,140 A 1/1964 Heeker wherein R is selected from —OCH —OCHCH, —CH, 3,166.577 A 1/1965 Ringold et al. —CHCH, CCCH, -CHCH-CH, or CH, CHCH: 3.410,879 A 11, 1968 Smith et al. and one or more anti-rheumatic agents. A method of using the 3,470,218 A 9, 1969 Farah 3,492.321 A 1, 1970 Crabbe composition for treating rheumatic diseases in humans and 3,496,272 A 2/1970 Kruger animals is also disclosed. 3,562.260 A 2, 1971 De Ruggieri et al. 3,956,348 A 5, 1976 HillScher 8 Claims, 8 Drawing Sheets N = 10 mice group - Vice control 5 va2ME2 mg/kg -a2ME20mg/kg c-2ME2100mg/kg O Araritic Score O = no signs of arthritis = rednessfredspots on paw 22 partialswelling, difficultles with stretching paw 3 swelling no loading on 5 paw O 5 O 4a maxlmally swoller paw, Time (days) no loading p-0.05 US 8,399.440 B2 Page 2 U.S. PATENT DOCUMENTS 2004/0082558 A1 4/2004 Tofovic et al. 4,634,705 A 1, 1987 DeBernardis et al. 2004/01 16397 Al 6/2004 Slaga et al. 4.743,597 A 5, 1988 Javitt et al. 2004/O121968 A1 6, 2004 Ljubimov 4,808.402 A 2f1989 Leibovich et all 2004/O156854 A1 8/2004 Mulligan et al. 4,994.443 A 2, 1991. Foll etal 2004/O186086 A1 9/2004 Bunschoten et al. 5.00. 16 A 3, 1991. Foll et al. 2004/O198671 A1 10, 2004 Bunschoten et al. 535.99 A 8, 1992 Fol et al. 2004/0209855 A1 10, 2004 Tofovic et al. 5,166,149 A * 11, 1992 Loev in a . 514, 186 2004/0214807 A1 10, 2004 D'Amato et al. 5,252,718 A 10, 1993 Baird et al. 2005, OO14737 A1 1/2005 Agoston et al. 5,504,074 A 4, 1996 D'Amato et al. 2005/OO32766 A1 2, 2005 Green et al. 5.531.168 A 5, 1996 Clark 2005, 0070488 A1 3/2005 Coelingh Bennik et al. 562.24 A 4/1997 Seilz et all 2005/0101573 A1 5/2005 Faarup et al. 5620327 A 5, 1997 D’Amato 2005, 014.8565 A1 7/2005 Cooperwood 5629.340 A 5, 1997 Kuwano et al. 2005, 0182038 A1 8/2005 Cooperwood 5,639,725 A 6/1997 O'Reilly et al. 2005/01922.58 A1 9/2005 Agoston et al. 5,646,1365,643,900 A * 7,7/1997 1997 PetrowFotsis et al. ................... 514, 182 3.339:29. A1 11/2005299 Leeg, et al. 566.143 A 8, 1997 D'Amato et all 2005/0266.067 A1 12, 2005 Sengupta et al. 576.981 A 2f1998 Hunter et all 2006.0025393 A1 2/2006 Liao et al. 573.3876 A 3/1998 O’Reilly et al 2006.0025619 A1 2/2006 Agoston et al. 5763.432 A 6, 1998 Tanabe et al. 2006, OO79576 A1 4/2006 D'Amato 5,776.704 A 7/1998 O’Reilly et al. 2006, O116360 A1 6/2006 Fogler 5,792,845 A 8/1998 O’Reilly et al. 2006/0135796 A1 6/2006 Agoston 5,837.682. A 1 1/1998 O’Reilly 2007/0135400 A1 6/2007 Agoston et al. 5,854.205 A 12/1998 O’Reilly et al. 2007,0185.069 A1 8, 2007 Plum et al. 5,854.221 A 12/1998 Cao et al. 5,861.372 A 1/1999 Folkman et al. FOREIGN PATENT DOCUMENTS 5,885,795 A 3/1999 O’Reilly et al. DE 27 57 157 12, 1977 5,892,069 A 4/1999 D'Amato et al. DE 3625315 1, 1988 5,919,459 A 7/1999 Nacy et al. EP O166937 A2 8, 1986 5,958,892 A 9/1999 Mukhopadhyay et al. EP 0281822 A2 9, 1988 5,962.445 A 10, 1999 Stewart EP O657175 A2 6, 1995 6,011,023 A 1/2000 Clarket al. GB 857080 12, 1960 6,011,024 A 1/2000 Reed et al. GB 857081 12, 1960 6,046,186 A 4/2000 Tanabe et al. GB 1570597 T 1980 6,051,726 A 4/2000 Sachdeva et al. GB 2252498 A 8, 1992 6,054,598 A 4/2000 Sachdeva et al. JP 39-5480 B Of OOOO 6,136,992 A 10, 2000 Ram et al. JP 41 OOO 100 A 1, 1966 6,200,966 B1 3, 2001 Stewart JP 42000928 B 1, 1967 6,239,123 B1 5, 2001 Green JP 62-135472 6, 1987 6,284,789 B1 9/2001 LaLonde et al. JP 63090763 A 4f1988 6,346,510 B1 2/2002 O'Reilly et al. JP 63-119500 5, 1988 6,358,940 B1 3/2002 Conney JP 04-046120 2, 1992 6,399,773 B1 6, 2002 Liu et al. WO WO 87,02367 A3 4f1987 6,407,086 B2 6/2002 Faarup et al. WO WO 88,03151 A2 5, 1988 6.410,029 B1 6/2002 Mukhopadhyay et al. WO WO 88.08.002 A1 10, 1988 6,413.513 B1 7/2002 Holaday et al. WO WO90, 1581.6 A1 12/1990 6,448,419 B1 9, 2002 Paaren et al. WO WO93,03729 A1 3, 1993 6,514,971 B1 2/2003 Thomas et al. WO WO93/10805 A1 6, 1993 6,528,676 B1 3/2003 D'Amato et al. WO WO93, 19746 A1 10, 1993 6,593,321 B2 7/2003 Rao et al. WO WO 94.21288 A1 9, 1994 6,605,622 B2 8, 2003 Green et al. WO WO95/04535 A1 2, 1995 6,723,858 B2 4/2004 D’Amato et al. WO WO 98.32763 A1 7, 1998 6,730,665 B1 5, 2004 Maran et al. WO WO98,40398 9, 1998 6,759,386 B2 7/2004 Franco WO WO 9901142 A1 1, 1999 6,852,710 B2 2/2005 Rao et al. WO WO99.22728 A1 5, 1999 6,908,910 B2 6, 2005 D'Amato et al. WO WO99/33858 A3 7, 1999 6,930,128 B2 8, 2005 D'Amato et al. WO WO99/33859 A2 7, 1999 6,953,785 B2 10/2005 Ino et al. WO WO99,35150 A3 7, 1999 6,995,278 B2 2/2006 Agoston et al. WO WO99/45O18 A1 9, 1999 6,998,395 B2 2, 2006 Jackson et al. WO WOOOf O7576 A2 2, 2000 7,012,070 B2 3, 2006 D'Amato et al. WO WOOOf 10552 A2 3, 2000 7,081,477 B2 7/2006 D'Amato et al. WO WOOOf 66095 A2 11/2000 7,087,592 B1 8/2006 Agoston WO WOOO68246 A1 11, 2000 7,109,187 B2 9, 2006 D'Amato et al. WO WOO1?27132 A1 4/2001 7,135,581 B2 11/2006 Agoston et al. WO WOO1f85755 A1 11, 2001 7,291,610 B2 11/2007 D'Amato et al. WO WO O2, 1591.0 A1 2, 2002 7,351,729 B2 4/2008 Stein et al. WO WO 2004/074307 A1 9, 2004 7,371,741 B2 5/2008 Agoston et al. WO WO 2004f101595 A1 11, 2004 7,381,848 B2 6, 2008 D'Amato et al. WO WO 2005/089.256 A2 9, 2005 2002.0002294 A1 1/2002 D'Amato et al. WO WO 2007/059111 A2 5/2007 2002fOO35098 A1 3/2002 Slaga et al. 2002.0068724 A1 6/2002 Slaga et al. 2003/0027803 A1 2/2003 Slaga et al. OTHER PUBLICATIONS 38.933 A. 33. S. s al Office Action cited in U.S. Appl. No. 10/789,471 mailed Aug. 18. 2003/0096799 A1 5, 2003 Rao et al. 2009, USPTO Office Action, pp.